3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
5
Paraproteinemias
1
Amyloidosis
1
Alzheimer Disease
1
Interventions
XENP 1595
2
birtamimab
1
UE2343
1
Rosiglitazone
1
Propofol
1
Positron-Emission Tomography
1
Methotrexate
1
Electroencephalography
1
Donepezil
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Alzheimer Disease
×
birtamimab
×
Clear all
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts